Carlos Simon

Has grant

Professor of Obstetrics & Gynecology

Baylor College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Identification of maternal cellular and molecular targets at the single-cell level for early prediction and treatment of preeclampsia

Open Date: 2023-01-01

Close Date: 2027-01-01

Grant: Close

Preventing lifetime obesity by early risk-factor identification, prognosis, and intervention. (eprObes)

Open Date: 2023-01-01

Close Date: 2026-01-01

Grant: Close

Deciphering a microbial footprint leading to onset and long-term risk of preeclampsia (PREMIC)

Open Date: 2023-01-01

Close Date: 2026-01-01

Grant: Close

Human Uterus Cell Atlas (HUTER)

Open Date: 2020-01-01

Close Date: 2022-01-01

Grant: Close

Innovative Training Network in Female Reproductive Care

Open Date: 2019-01-01

Close Date: 2023-01-01

Articles (16)

The generation of human embryos in vitro has revolutionized reproductive medicine, and also made it possible to study fundamental aspects of early human development. However, human preimplantation embryos often display an array of morphological defects associated with poor development and implantation. Here, we used live-embryo imaging and computational analysis to capture how these defects can be produced in real time. We record various forms of mitotic errors including lagging chromosomes producing micronuclei, multipolar spindles causing abnormal chromosome organization recapitulated by daughter cells, and uncontrolled scattering of condensed chromosomes. In addition, we capture abnormal cleavage furrow dynamics during cytokinesis producing binucleated and enucleated cells. Finally, we find cells with disrupted mitotic progression ultimately leading to blebbing and fragmentation. Thus, these results document specific aberrant cell behaviors producing morphological defects in real time, and indicate that errors during mitosis and cytokinesis represent a major cause of developmental failures in human embryos.

Year:

2025

Autologous CD133 + bone marrow-derived stem cell (BMDSC) therapy has been designated an Orphan Drug by the EMA and FDA for the treatment of Asherman Syndrome (AS). This phase 1/2, non-randomized, open-label, single-arm trial assessed the safety, efficacy and biological plausibility of this novel therapy in 20 infertile women with moderate to severe AS unresponsive to prior hysteroscopic treatments. The primary endpoint was safety, with doses ranging from 31 to 212 × 10⁶ cells being well tolerated; reversible limb paresthesia was the most common adverse event. Secondary endpoints demonstrated significant improvements in endometrial morphometry, thickness (3.80 ± 0.95 mm to 5.29 ± 0.77 mm, p < 0.05), endometrial volume (1.26 cm³ to 2.78 cm³, p < 0.05), and hysteroscopic scores (8.0 ± 3.17 to 4.42 ± 2.09, p < 0.05). Clinically, menstruation and reproductive function were restored, culminating in six live births following embryo transfer. Single-cell RNA sequencing of endometrium and organoids pre- and post-treatment revealed partial reversion of AS-related changes. Additionally, mitochondrial variant tracking offered insights into the engraftment of transplanted CD133 + BMDSCs. These findings suggest that autologous CD133 + BMDSC therapy is a safe and effective treatment for moderate to severe AS, warranting further investigation in larger trials.

Year:

2025

Disruptions in uterine tissue function contribute to disorders such as endometriosis, adenomyosis, endometrial cancer, and fibroids, which all significantly impact health and fertility. Advances in transcriptomics, particularly single-cell RNA sequencing, have revolutionized uterine biological research by revealing the cellular heterogeneity and molecular mechanisms underlying disease states. Single-cell RNA sequencing and spatial transcriptomics have mapped endometrial and myometrial cellular landscapes, which helped to identify critical cell types, signaling pathways, and phase-specific dynamics. Said transcriptomic technologies also identified stromal and immune cell dysfunctions, such as fibroblast-to-myofibroblast transitions and impaired macrophage activity, which drive fibrosis, chronic inflammation, and lesion persistence in endometriosis. For endometrial cancer, scRNA-seq uncovered tumor microenvironmental complexities, identifying cancer-associated fibroblast subtypes and immune cell profiles contributing to progression and therapeutic resistance. Similarly, studies on adenomyosis highlighted disrupted signaling pathways, including Wnt and VEGF, and novel progenitor cell populations linked to tissue invasion and neuroinflammation, while single-cell approaches characterized smooth muscle and fibroblast subpopulations in uterine fibroids, elucidating their roles in extracellular matrix remodeling and signaling pathways like ERK and mTOR. Despite challenges such as scalability and reproducibility, single-cell transcriptomic approaches may have potential applications in biomarker discovery, therapeutic target identification, and personalized medicine in gynecological disorders.

Year:

2025

Early-onset (EOPE) and late-onset preeclampsia (LOPE) pose significant challenges to maternal and child health, highlighting the need for early, non-invasive risk identification. In this prospective longitudinal study, we followed 9,586 pregnant women, collecting blood samples each trimester: 9-14 weeks (T1), 18-28 weeks (T2), and after 28 weeks or at preeclampsia diagnosis (T3). Plasma cell-free RNA (cfRNA) signatures were analyzed in women who developed EOPE (n=42) or LOPE (n=43) and compared to matched normotensive controls (n=75). Mapping cfRNA origins and performing differential abundance analysis provided insights into multi-organ impacts, revealing distinct transcriptional features of EOPE and LOPE. We developed a first-trimester EOPE predictive model using 36 transcripts, achieving 83% sensitivity, 88% specificity, and an AUC of 0.85, detecting risk 18.0 weeks before onset. A second-trimester model based on 87 cfRNA transcripts, predicted EOPE 8.5 weeks prior to onset with 87% sensitivity, 84% specificity, and an AUC of 0.85. For LOPE model, detecting risk 14.9 weeks before onset, used 92 cfRNAs, with 86% sensitivity, 89% specificity, and an AUC of 0.88. EOPE models were enriched for decidua-associated transcripts, highlighting the maternal involvement in this subtype, while LOPE models showed diverse tissue responses, paving the way for improved subtype differentiation and tailored interventions to mitigate preeclampsia risks.

Year:

2025

Endometrial decidualization resistance (DR) is implicated in various gynaecological and obstetric conditions. Employing a multi-omic strategy, we unraveled the cellular and molecular characteristics of DR in patients that have suffered severe preeclampsia (sPE). Morphological analysis unveiled significant glandular anatomical abnormalities, confirmed histologically. Single-cell RNA sequencing (scRNA-seq) of endometrial samples from sPE cases (n=11) and controls (n=12) revealed sPE-associated shifts in cell composition, manifesting as a stromal mosaic state characterized by proliferative stromal cells (MMP11, SFRP1+) alongside IGFBP1+ decidualized cells, with concurrent epithelial mosaicism and a dearth of epithelial-stromal transition associated with decidualization. Cell-cell communication network mapping underscored aberrant crosstalk among specific cell types, implicating crucial pathways such as endoglin and WNT. Spatial transcriptomics in a replication cohort validated DR-associated features. Laser capture microdissection/mass spectrometry in a second replication cohort corroborated several scRNA-seq findings, notably the absence of stromal to epithelial transition at a pathway level, indicating disrupted response to steroid hormones, particularly estrogens. These insights shed light on potential molecular mechanisms underpinning DR pathogenesis in the context of sPE.

Year:

2024

Age-associated myometrial dysfunction can prompt complications during pregnancy and labor, which is one of the factors contributing to the 7.8-fold increase in maternal mortality in women over 40. Using single-cell/single-nucleus RNA sequencing and spatial transcriptomics, we have constructed a cellular atlas of the aging myometrium from 186,120 cells across twenty perimenopausal and postmenopausal women. We identify 23 myometrial cell subpopulations, including contractile and venous capillary cells as well as immune-modulated fibroblasts. Myometrial aging leads to fewer contractile capillary cells, a reduced level of ion channel expression in smooth muscle cells, and impaired gene expression in endothelial, smooth muscle, fibroblast, perivascular, and immune cells. We observe altered myometrial cell-to-cell communication as an aging hallmark, which associated with the loss of 25 signaling pathways, including those related to angiogenesis, tissue repair, contractility, immunity, and nervous system regulation. These insights may contribute to a better understanding of the complications faced by older individuals during pregnancy and labor.

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Xavier Santamaria

Investigador biomédico, especialidad ginecología

Vall d'Hebron Institut de Recerca

SPAIN
View details

Rosa Noguera

-

SPAIN
View details

Mar Gil

Professor

Baylor College of Medicine

UNITED STATES
View details

Rafael Badenes

Professor

University of Valencia

SPAIN
View details